PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
28 hedge funds and large institutions have $1.1M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2014 Q2 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$365K |
| 2 |
U
UBS
Zurich,
Switzerland
|
+$292K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$240K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$105K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$97.7K |
Top Sellers
PVCT Hedge Fund Activity: Q2 2014 in Review
28 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2014, worth a combined $1.1M.
Buyers outnumbered sellers: 28 funds opened new PVCT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $365K.
- 28 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $1.1M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2014.
- 28 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2014 and 0 closed out, a net change of +28 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q2 2014 was Goldman Sachs, an estimated $365K added.
Based on aggregated 13F filings for Q2 2014.